Servier Presentations At ASCO 2025 Reinforce Company Leadership In IDH-Mutated Cancers

(MENAFN- PR Newswire)

BOSTON, May 22, 2025 /PRNewswire/ -- Servier today announced that it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on May 30 – June 3 in Chicago.

Presentations will span across a range of cancers including chondrosarcoma, cholangiocarcinoma and myelodysplastic syndrome, reinforcing Servier's commitment to the development of precision medicines for isocitrate dehydrogenase (IDH) mutated cancers.

"As industry leaders in IDH-mutated cancers, we look forward to sharing updates regarding the expansion of our clinical development program at this year's ASCO," said Becky Martin, PhD, Chief of Medical at Servier Pharmaceuticals. "Innovation in precision medicine, including targeted therapies, is critical to improving outcomes for people living with cancer, and we are pleased to share updates on several Phase 3 programs that have the potential to bring new options to patients living with IDH-mutated cancers."

A full list of company-sponsored abstracts to be presented at ASCO can be found here .

In addition to its presence at ASCO, Servier will also present research updates at the 30^th European Hematology Association (EHA) Congress on June 12-15 in Milan.

Media Contact
Sara Noonan: [email protected] I Tel. +1 857 262 3855

About Servier in Oncology
Servier is a global leader in oncology, governed by a non-profit foundation. Servier approaches innovation with a long-term vision, free of influence from fiduciary responsibilities.

Servier is the leader in IDH-mutant targeted therapies and devotes more than 65% of its research and development budget to Oncology. Servier aspires to advance more targeted therapies by identifying mutations and understanding how these mutations impact cancer and its progression. Servier believes we can serve more people by helping the right patients find the right treatment, at the right time.

Servier takes a One Innovation Engine approach to R&D and is actively seeking alliances, partnerships and acquisitions at various stages of the portfolio.

For more information about working with Servier to bring the promise of tomorrow to the patients it serves, visit Servier .

SOURCE Servier Pharmaceuticals

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN22052025003732001241ID1109585029